CVS Health Expands Access to GLP-1 Weight Management Medications

In a significant move aimed at improving affordability and access to weight management medications, CVS Health (NYSE: CVS) announced an expansion of its coverage options for GLP-1 medications. The press release dated May 28, 2026, reveals CVS Caremark's plans to reintroduce Zepbound® (tirzepatide) to its commercial formularies and remove the new-to-market block on the oral GLP-1 therapy, Foundayo™ (orforglipron). These updates are a part of CVS Caremark's ongoing efforts to make FDA-approved weight management therapies more accessible and affordable for its members.

Beginning October 1, 2026, CVS Caremark will reinstate Zepbound as a preferred option in its commercial formularies. This change is designed to enhance access to GLP-1 medications at a more affordable price for plan sponsors who choose to provide coverage for these therapies.

Effective June 1, 2026, CVS Caremark will also eliminate the new-to-market block on Foundayo, further broadening the options available to its members. This oral GLP-1 therapy will now be accessible for coverage where approved by health plans, marking a significant step forward in the quest for affordable weight management solutions.

CVS Caremark's proactive approach in the GLP-1 weight management sector underscores its commitment to driving down costs. Over the past year, the company has focused on negotiating with pharmaceutical manufacturers to create a pricing structure that benefits both customers and their members.

Ed DeVaney, President of CVS Caremark, emphasized the importance of these changes, stating, "We're creating access and options that would not have existed without our leadership in the market." The company’s bold engagement with drug manufacturers has been pivotal in addressing affordability challenges.

Despite the clinical advancements presented by GLP-1 medications, their high prices have historically limited access for many potential beneficiaries. CVS Caremark’s efforts to negotiate better pricing aim to alleviate the financial strain these medications can impose on health plans and, subsequently, on patients.

As demand for GLP-1 medications remains high, CVS Caremark recognizes the challenges faced by plan sponsors who have had to make difficult decisions to limit coverage in order to maintain balanced benefit programs. The company’s ongoing collaboration with pharmaceutical firms is a crucial part of its strategy to make these essential medications more accessible.

A formulary is a list of prescription medications that a health plan covers, managed by pharmacy benefit managers like CVS Caremark. These formularies are regularly evaluated and can be customized by plan sponsors to meet the needs of their populations.

The ability to customize formularies allows health plans to provide clinically appropriate treatments while managing overall medication costs. CVS Caremark's updates aim to support member access to these treatments, ultimately enhancing patient care.

CVS Caremark is committed to ensuring a smooth transition for customers and members affected by these formulary changes. The company plans to provide proactive communication, educational resources, and clinical support programs to facilitate this transition.

The latest updates from CVS Health reflect a strategic move to enhance the affordability and accessibility of GLP-1 weight management medications. With the reintroduction of Zepbound and the removal of barriers for Foundayo, CVS Caremark is positioning itself as a leader in the ongoing effort to tackle rising prescription drug costs and improve access for millions of Americans. As the healthcare landscape continues to evolve, CVS Health remains dedicated to simplifying healthcare and delivering better outcomes for its members.